Tests emapalumab as an early treatment for young people with aplastic anemia
Tests emapalumab given first in children and young adults with aplastic anemia.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Cincinnati, Milwaukee, New York, Philadelphia, and Richmond, United StatesSee the 6 sites
- Trial code
- Registry title
- A Study of Emapalumab for Pediatric Aplastic Anemia
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 35 people, planned
- Started
- 21 May 2024
- Expected to end
- 21 May 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Emapalumab
- Record updated
- 17 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people under 25 with suspected new severe aplastic anemia, before they have had any treatment for it.
- Age
- Under 25 years at diagnosis (0 to 25 years).
- Sex
- All sexes can join.
- Disease stage
- Suspected newly diagnosed severe aplastic anemia: low bone marrow cell count (cellularity under 25%, or 25-50% with under 30% residual blood-forming cells) and at least 2 of 3 low blood counts (neutrophils under 500 x 10^9/L, platelets under 20 x 10^9/L, reticulocytes under 60 x 10^9/L).
- Earlier treatment
- People who have already been treated for severe aplastic anemia cannot join.
Main reasons for not taking part
- Uncontrolled infection when they come in
- Earlier treatment for severe aplastic anemia
- Known inherited bone marrow failure
- Leukemia or MDS
- Full workup done, donor ready, and stem cell transplant planned within 2 weeks of joining
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients undergoing workup for suspected newly diagnosed sAA:; Patients with severe cytopenias and a hypocellular marrow concerning for sAA; Patients that meet the definition for suspected sAA (Camitta Criteria) as follows:; Marrow Cellularity: <25%, or 25-50% with <30% residual hematopoietic cells Peripheral cytopenias (at least 2 of 3) Absolute neutrophil count (ANC): <500 x 10\^9/L Platelets: <20 x 10\^9/L Absolute Reticulocyte Count: <60 x 10\^9/L
- Patients that do not have evidence of leukemia or MDS
- Patients < 25 years of age at time of diagnosis
- Able to tolerate emapalumab and IST (with standard institutional organ function criteria)
Who cannot take part
- Patients who have undergone previous treatment for sAA
- Uncontrolled infection at presentation
- Patients with known inherited bone marrow failure
- Patient who has completed a full workup for sAA including having results back from telomere testing, DEB and genetics (when applicable), as well as having an appropriate willing and available donor and would otherwise be admitted for HSCT within 2 weeks of enrolling on the trial
- Patients with leukemia or MDS
- Patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 25 years old?
Where in United States
- Cincinnati Children's Hospital Medical Center (Data Collection Only)Cincinnati, United StatesContact: Anthony Sabulski, MDTaking people
- Children's Hospital of Wisconsin (Data Collection Only)Milwaukee, United StatesContact: Larisa Broglie, MDTaking people
- Medical College of Wisconsin (Data Collection AND Data Analysis)Milwaukee, United StatesContact: Larisa Broglie, MDNot yet recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Andromachi Scaradavou, MDTaking people
- Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis)Philadelphia, United StatesContact: Tim Olson, MD, PhDTaking people
- Virginia Commonwealth University (Data Collection Only)Richmond, United StatesContact: Joe Laver, MD, MHATaking people
About the trial
What the trial wants to find out
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.
Read full original descriptionShow less
Funding Source- FDA OOPD
The 2 groups in the trial
- Emapalumab, then Standard ISTTreatment being tested
Participants will first receive Emapalumab for 6 weeks. After treatment with emapalumab, participants will receive standard IST with drugs called equine anti-thymocyte globulin (hATG) and cyclosporin (CsA) in addition to a lower dose of emapalumab
Treatment: Emapalumab
- Emapalumab, then HCTTreatment being tested
Participants will first receive Emapalumab for 6 weeks. After treatment with emapalumab, participants will have a standard hematopoietic stem cell transplant (HCT).
Treatment: Emapalumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia
- Plain-language title
- Tests emapalumab as an early treatment for young people with aplastic anemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06430788, who can take part
- Record updated
- 17 December 2025